Vivex Biologics Says VIA Disc NP Met Primary Endpoint in ASCEND Trial
Vivex Biologics said VIA Disc NP met the primary endpoint in the pivotal, sham-controlled ASCEND trial, published in the Journal of Clinical Medicine.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.